Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2022-01-12 Regulatory Filings
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Biotest AG: Biotest AG opens eighth plasma collection centre in Czech Republic
Regulatory Filings Classification · 100% confidence The document is a press release announcing a specific operational update: Biotest AG opening its eighth plasma collection centre in the Czech Republic. It is not a comprehensive financial report (like 10-K or IR), nor is it a transcript, an earnings release, or a formal proxy statement. It is a piece of corporate news disseminated via DGAP (a service often used for regulatory announcements). Since it details a business development that doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), it falls best under the general regulatory announcement category, which serves as a fallback for miscellaneous corporate news that is not strictly financial reporting or a formal meeting material. Given the nature of the announcement (operational expansion), it is best classified as a general Regulatory Filing (RNS) as it is a public disclosure of material, non-financial business information.
2022-01-12 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' under German securities law (WpHG). It reports changes in voting rights percentages (crossing thresholds) held by UBS Group AG in Biotest AG. This directly corresponds to the definition of reporting changes in significant share ownership levels, which aligns with the Major Shareholding Notification category (MRQ). Although it mentions 'Voting Rights Announcements' in the header, the content is a specific regulatory filing about share ownership thresholds, making MRQ the most precise fit over the general DVA (Declaration of Voting Results) or RNS (Regulatory Filings).
2022-01-10 English
Biotest AG: Grifols, S.A. will hold more than 95,5498 % of the voting rights upon settlement of the takeover offer
M&A Activity Classification · 100% confidence The document is an 'Ad-hoc RELEASE' dated January 7, 2022, announcing that Grifols, S.A. will hold over 95.5498% of the voting rights in Biotest AG upon settlement of a takeover offer. It explicitly references MAR (Market Abuse Regulation) and WpÜG (German Securities Acquisition and Takeover Act). This content directly relates to a takeover bid and the resulting change in control/shareholding structure. This falls under the category of M&A Activity (TAR) or potentially Major Shareholding Notification (MRQ). Since the core subject is the successful outcome of a 'takeover offer' and the subsequent intention to initiate a 'squeeze-out' (a direct consequence of a successful takeover), TAR (Merger/Takeover Activity) is the most precise classification. It is not a standard regulatory filing like 10-K or IR, nor is it a simple announcement of a report (RPA).
2022-01-07 English
Biotest AG: Biotest treats first CMV-positive pregnant woman in Phase III clinical trial to prevent transmission of CMV infection to the unborn child
Regulatory Filings Classification · 99% confidence The document is a press release dated December 14, 2021, announcing a clinical trial update: 'Biotest treats first CMV-positive pregnant woman in Phase III clinical trial'. It details the progress of a clinical study (PreCyssion trial) for a specific drug (Cytotect CP Biotest (R)) and discusses the medical need and expected outcomes. This type of announcement, focusing on research progress, clinical trial milestones, and product development updates, is best classified as a general corporate news release that doesn't fit the specific financial report categories (like 10-K, ER, IR). Since it is a specific corporate announcement disseminated via DGAP (a service often used for regulatory news), and it doesn't fit the definitions for ER (Earnings Release), IR (Interim Report), or LTR (Legal Proceedings), the most appropriate general category for specific, non-financial corporate updates that are not explicitly defined elsewhere is Regulatory Filings (RNS), which serves as a broad category for official company announcements not covered by other specific codes. It is not an Earnings Release (ER) as it discusses clinical trials, not financial results. It is not a Report Publication Announcement (RPA) because it contains substantive news content, not just a notice that a report is available.
2021-12-14 English
Biotest AG: Biotest Supervisory Board appoints new Management Board member
Board/Management Information Classification · 100% confidence The document is a press release dated December 9, 2021, announcing a personnel change: the appointment of Dr. Jörg Schüttrumpf to the Management Board as Chief Scientific Officer (CSO). This directly relates to changes in senior management personnel. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document structure (DGAP-News, PRESS RELEASE) confirms it is an official announcement, not a comprehensive report or a general regulatory filing.
2021-12-09 English
Biotest AG: Biotest adjusts guidance
Earnings Release Classification · 99% confidence The document is a press release dated December 8, 2021, issued via DGAP-News, announcing that Biotest AG is adjusting its EBIT guidance for 2021 due to issues with coagulation factor production and raw material depreciation. This is a material financial update that is not a full annual report (10-K), a comprehensive interim report (IR), or a simple dividend/share transaction notice. It is an announcement of a change in expected financial performance, specifically a profit warning/guidance revision. This fits best under the 'Earnings Release' (ER) category, which covers initial announcements of periodical financial results or significant updates affecting those results, or potentially 'Regulatory Filings' (RNS) as a general announcement. Given the content is a direct revision of expected financial results (EBIT guidance), ER is the most specific fit, as it signals a major change in expected earnings figures, even if it's not the final quarterly report itself. It is not a Call Transcript (CT), Investor Presentation (IP), or Management Discussion (MDA). FY 2021
2021-12-08 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.